10-K · February 24, 2026
Fulcrum positions itself as a clinical-stage small-molecule company focused on rapidly developing pociredir for sickle cell disease (SCD) and applying its discovery platform to complementary benign hematology programs.…
Earnings analysis · 10-Q
FULC earnings analysis
Filed April 27, 2026 · Our reading of the company's report
The latest report
Fulcrum reported a net loss of $18.9 million for Q1 2026 versus $17.7 million a year earlier, while continuing to advance pociredir with strong PIONEER 20 mg cohort PD data (mean absolute HbF +12.2% to 19.3% at Week…
Read full summary
Fulcrum reported a net loss of $18.9 million for Q1 2026 versus $17.7 million a year earlier, while continuing to advance pociredir with strong PIONEER 20 mg cohort PD data (mean absolute HbF +12.2% to 19.3% at Week 12). The company ended the quarter with $333.3 million in cash, cash equivalents and marketable securities and states this balance is expected to fund operations into 2029. R&D and G&A rose modestly (R&D $14.084M; G&A $8.102M), and management plans to provide next-trial design details in Q2 2026 and, pending FDA feedback, may initiate a registration‑enabling trial in H2 2026.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Strong cash runway
As of March 31, 2026, the company had $333.3 million in cash, cash equivalents and marketable securities and states this will enable funding of operations into 2029 ("we had $333.3 million ... will enable us to fund ... into 2029").
-
Positive PIONEER 20 mg cohort data
Updated 20 mg cohort results show mean absolute HbF increased by 12.2% at 12 weeks, rising from 7.1% baseline to 19.3% and with 7 of 12 patients (58%) achieving ≥20% HbF at Week 12.
-
R&D investment increasing with program focus
Total R&D expense rose to $14.084 million for Q1 2026 from $13.404 million in Q1 2025, driven by increased employee compensation (internal R&D $5.371M) and pociredir external expenses of $5.414M.
-
Operational spending modestly higher
Total operating expenses increased to $22.186 million in Q1 2026 from $20.403 million in Q1 2025, with G&A increasing to $8.102 million from $6.999 million (Δ $1.103M).
-
Clinical development timeline defined
Management plans to provide next-trial design details in Q2 2026 following End‑of‑Phase FDA meeting minutes and, pending FDA feedback, plans to initiate a potential registration‑enabling trial in the second half of 2026.
-
Narrowing program focus
Based on IND‑enabling results, the company decided not to advance the bone marrow failure syndromes program into clinical development and in April 2026 provided notice to terminate the CAMP4 license agreement.
What to watch
-
Continued quarterly losses
Net loss was $18.891 million for the three months ended March 31, 2026, up $1.236 million from $17.655 million for the three months ended March 31, 2025.
-
Large accumulated deficit
As of March 31, 2026 the company reported an accumulated deficit of $613.2 million.
-
Need for additional funding remains
MD&A states the company "will need substantial additional funding" and may finance operations through equity, debt, collaborations or licensing if product revenues do not materialize.
-
Pipeline concentration and program terminations
The company chose not to advance its bone marrow failure program into clinical development and terminated the CAMP4 license in April 2026, concentrating resources on pociredir and core benign hematology programs.
-
Operating expense pressure
Total operating expenses rose to $22.186 million (R&D $14.084M; G&A $8.102M), increasing the cash burn profile versus prior year.
-
Reduced diversification of external programs
External losmapimod expense dropped to $0 in Q1 2026 from $1.024 million in Q1 2025, reflecting fewer externally funded programs.
Management's outlook
No numeric revenue or EPS guidance provided. Management states existing cash, cash equivalents and marketable securities of $333.3 million 'will enable us to fund our operating expenses and capital expenditure requirements into 2029.' Company expects to provide next‑trial design details in Q2 2026 and, pending FDA feedback, may initiate a registration‑enabling trial in H2 2026.
Earlier filings 4
10-K · February 25, 2025
Fulcrum is a clinical-stage biotech focused on pociredir (an oral HbF inducer for sickle cell disease). The company suspended losmapimod after a failed Phase 3 in FSHD, cut headcount from 80 to 51 and expects ~$10.0M of…
10-Q · May 13, 2024
Fulcrum reported Q1 results with collaboration revenue of $0 (Q1 2023: $295) and a net loss of $26,870, resulting in GAAP diluted EPS of $(0.43) (Q1 2023: $(0.41)). Cash and marketable securities remain sizable at…
10-Q · November 7, 2023
Fulcrum reported collaboration revenue of $759,000 in Q3 2023 (down from $1,183,000 in Q3 2022) and a GAAP net loss of $24,017,000 (EPS -$0.39). Operating expenses rose to $28,199,000 driven by higher R&D of…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.